Table 1.
Antibiotic ophthalmic solutions evaluated in the present study
| Active component | Trade name | Preservative | CVS50* |
|---|---|---|---|
| Levofloxacin (0.5%) | Cravit (Santen, Osaka, Japan) Quixin (in US; Vistakon, Jacksonville, FL, USA; with 0.005% BAK) | No | 3 |
| Moxifloxacin (0.5%) | Vigamox (Alcon, Fort Worth, TX, USA) | No | 1 |
| Gatifloxacin (0.3%) | Gatiflo (Senju, Osaka, Japan) Zymar (in US; Allergan, Irvine, CA, USA; with 0.005% BAK) | No | 2 |
| Norfloxacin (0.3%) | Noflo (Banyu, Tokyo, Japan) | No | 2 |
| Tosufloxacin (0.3%) | Tosuflo (Nitto, Nagoya, Japan) | No | 3 |
| Dibekacin (0.5%) | Panimycin (Meiji, Tokyo, Japan) | No | 3 |
| Cefmenoxime (0.5%) | Bestron (Kaken, Tokyo, Japan) | 0.026% methyl paraoxybenzoate, 0.014% propyl paraoxybenzoate, boric acid | 4 |
Notes:
*
Number of cell lines with viability ≥50% in the presence of a 10-fold dilution of the drug.
Abbreviation: BAK, benzalkonium chloride.